Data sources for drug utilization research in Latin American countries-A cross-national study: DASDUR-LATAM study

Luciane C Lopes; Maribel Salas; Claudia Garcia Serpa Osorio-de-Castro; Lisiane Freitas Leal; Svetlana V Doubova; Martín Cañás; Anahi Dreser; Angela Acosta; Andre Oliveira Baldoni; Cristiane de Cássia Bergamaschi; Daniel Marques Mota; Diana L Gómez-Galicia; Dino Sepúlveda-Viveros; Edgard Narvaez Delgado; Elisangela da Costa Lima; Felipe Vera Chandia; Felipe Ferre; Gustavo H Marin; Ismael Olmos; Ivan R Zimmermann; Izabela Fulone; Juan Roldán-Saelzer; Juan Carlos Sánchez-Salgado; Lucila I Castro-Pastrana; Luiz Jupiter Carneiro de Souza; Manuel Machado Beltrán; Marcus Tolentino Silva; María Belén Mena; Marta Maria de França Fonteles; Martín A Urtasun; Mónica Tarapués; Patricia Granja Hernández; Natalia Medero; Raquel Herrera-Comoglio; Silvio Barberato-Filho; Taís Freire Galvão; Vera Lucia Luiza; Yared Santa-Ana-Tellez; Yesenia Rodríguez-Tanta; Monique Elseviers

doi:10.1002/pds.5404

Data sources for drug utilization research in Latin American countries-A cross-national study: DASDUR-LATAM study

Luciane C Lopes, Maribel Salas, Claudia Garcia Serpa Osorio-de-Castro, Lisiane Freitas Leal, Svetlana V Doubova, Martín Cañás, Anahi Dreser, Angela Acosta, Andre Oliveira Baldoni, Cristiane de Cássia Bergamaschi, Daniel Marques Mota, Diana L Gómez-Galicia, Dino Sepúlveda-Viveros, Edgard Narvaez Delgado, Elisangela da Costa Lima, Felipe Vera Chandia, Felipe Ferre, Gustavo H Marin, Ismael Olmos, Ivan R ZimmermannIzabela Fulone, Juan Roldán-Saelzer, Juan Carlos Sánchez-Salgado, Lucila I Castro-Pastrana, Luiz Jupiter Carneiro de Souza, Manuel Machado Beltrán, Marcus Tolentino Silva, María Belén Mena, Marta Maria de França Fonteles, Martín A Urtasun, Mónica Tarapués, Patricia Granja Hernández, Natalia Medero, Raquel Herrera-Comoglio, Silvio Barberato-Filho, Taís Freire Galvão, Vera Lucia Luiza, Yared Santa-Ana-Tellez, Yesenia Rodríguez-Tanta, Monique Elseviers

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

PURPOSE: Drug utilization research (DUR) contributes to inform policymaking and to strengthen health systems. The availability of data sources is the first step for conducting DUR. However, documents that systematize these data sources in Latin American (LatAm) countries are not known. We compiled the potential data sources for DUR in the LatAm region.

METHODS: A network of DUR experts from nine LatAm countries was assembled and experts conducted: (i) a website search of the government, academic, and private health institutions; (ii) screening of eligible data sources, and (iii) liaising with national experts in pharmacoepidemiology (via an online survey). The data sources were characterized by accessibility, geographic granularity, setting, sector of the data, sources and type of the data. Descriptive analyses were performed.

RESULTS: We identified 125 data sources for DUR in nine LatAm countries. Thirty-eight (30%) of them were publicly and conveniently available; 89 (71%) were accessible with limitations, and 18 (14%) were not accessible or lacked clear rules for data access. From the 125 data sources, 76 (61%) were from the public sector only; 46 (37%) were from pharmacy records; 43 (34%) came from ambulatory settings and; 85 (68%) gave access to individual patient-level data.

CONCLUSIONS: Although multiple sources for DUR are available in LatAm countries, the accessibility is a major challenge. The procedures for accessing DUR data should be transparent, feasible, affordable, and protocol-driven. This inventory could permit a comparison of drug utilization between countries identifying potential medication-related problems that need further exploration.

Original language	English
Pages (from-to)	343-352
Journal	Pharmacoepidemiology and Drug Safety
Volume	31
Issue number	3
Early online date	26 Dec 2021
DOIs	https://doi.org/10.1002/pds.5404
Publication status	Published - Mar 2022

Bibliographical note

Access to Document

10.1002/pds.5404Licence: CC BY-NC-ND

Pharmacoepidemiology and Drug - 2022 - LopesFinal published version, 2.7 MBLicence: CC BY-NC-ND

Cite this

Lopes, L. C., Salas, M., Osorio-de-Castro, C. G. S., Leal, L. F., Doubova, S. V., Cañás, M., Dreser, A., Acosta, A., Baldoni, A. O., de Cássia Bergamaschi, C., Mota, D. M., Gómez-Galicia, D. L., Sepúlveda-Viveros, D., Delgado, E. N., da Costa Lima, E., Chandia, F. V., Ferre, F., Marin, G. H., Olmos, I., ... Elseviers, M. (2022). Data sources for drug utilization research in Latin American countries-A cross-national study: DASDUR-LATAM study. Pharmacoepidemiology and Drug Safety, 31(3), 343-352. https://doi.org/10.1002/pds.5404

@article{12388699e9854b13bd04f0ca7a581522,

title = "Data sources for drug utilization research in Latin American countries-A cross-national study: DASDUR-LATAM study",

abstract = "PURPOSE: Drug utilization research (DUR) contributes to inform policymaking and to strengthen health systems. The availability of data sources is the first step for conducting DUR. However, documents that systematize these data sources in Latin American (LatAm) countries are not known. We compiled the potential data sources for DUR in the LatAm region.METHODS: A network of DUR experts from nine LatAm countries was assembled and experts conducted: (i) a website search of the government, academic, and private health institutions; (ii) screening of eligible data sources, and (iii) liaising with national experts in pharmacoepidemiology (via an online survey). The data sources were characterized by accessibility, geographic granularity, setting, sector of the data, sources and type of the data. Descriptive analyses were performed.RESULTS: We identified 125 data sources for DUR in nine LatAm countries. Thirty-eight (30%) of them were publicly and conveniently available; 89 (71%) were accessible with limitations, and 18 (14%) were not accessible or lacked clear rules for data access. From the 125 data sources, 76 (61%) were from the public sector only; 46 (37%) were from pharmacy records; 43 (34%) came from ambulatory settings and; 85 (68%) gave access to individual patient-level data.CONCLUSIONS: Although multiple sources for DUR are available in LatAm countries, the accessibility is a major challenge. The procedures for accessing DUR data should be transparent, feasible, affordable, and protocol-driven. This inventory could permit a comparison of drug utilization between countries identifying potential medication-related problems that need further exploration.",

author = "Lopes, {Luciane C} and Maribel Salas and Osorio-de-Castro, {Claudia Garcia Serpa} and Leal, {Lisiane Freitas} and Doubova, {Svetlana V} and Mart{\'i}n Ca{\~n}{\'a}s and Anahi Dreser and Angela Acosta and Baldoni, {Andre Oliveira} and {de C{\'a}ssia Bergamaschi}, Cristiane and Mota, {Daniel Marques} and G{\'o}mez-Galicia, {Diana L} and Dino Sep{\'u}lveda-Viveros and Delgado, {Edgard Narvaez} and {da Costa Lima}, Elisangela and Chandia, {Felipe Vera} and Felipe Ferre and Marin, {Gustavo H} and Ismael Olmos and Zimmermann, {Ivan R} and Izabela Fulone and Juan Rold{\'a}n-Saelzer and S{\'a}nchez-Salgado, {Juan Carlos} and Castro-Pastrana, {Lucila I} and {de Souza}, {Luiz Jupiter Carneiro} and Beltr{\'a}n, {Manuel Machado} and Silva, {Marcus Tolentino} and Mena, {Mar{\'i}a Bel{\'e}n} and {de Fran{\c c}a Fonteles}, {Marta Maria} and Urtasun, {Mart{\'i}n A} and M{\'o}nica Tarapu{\'e}s and Hern{\'a}ndez, {Patricia Granja} and Natalia Medero and Raquel Herrera-Comoglio and Silvio Barberato-Filho and Galv{\~a}o, {Ta{\'i}s Freire} and Luiza, {Vera Lucia} and Yared Santa-Ana-Tellez and Yesenia Rodr{\'i}guez-Tanta and Monique Elseviers",

note = "{\textcopyright} 2021 John Wiley & Sons Ltd.",

year = "2022",

month = mar,

doi = "10.1002/pds.5404",

language = "English",

volume = "31",

pages = "343--352",

journal = "Pharmacoepidemiology and Drug Safety",

issn = "1053-8569",

publisher = "John Wiley and Sons Ltd",

number = "3",

}

Lopes, LC, Salas, M, Osorio-de-Castro, CGS, Leal, LF, Doubova, SV, Cañás, M, Dreser, A, Acosta, A, Baldoni, AO, de Cássia Bergamaschi, C, Mota, DM, Gómez-Galicia, DL, Sepúlveda-Viveros, D, Delgado, EN, da Costa Lima, E, Chandia, FV, Ferre, F, Marin, GH, Olmos, I, Zimmermann, IR, Fulone, I, Roldán-Saelzer, J, Sánchez-Salgado, JC, Castro-Pastrana, LI, de Souza, LJC, Beltrán, MM, Silva, MT, Mena, MB, de França Fonteles, MM, Urtasun, MA, Tarapués, M, Hernández, PG, Medero, N, Herrera-Comoglio, R, Barberato-Filho, S, Galvão, TF, Luiza, VL, Santa-Ana-Tellez, Y, Rodríguez-Tanta, Y & Elseviers, M 2022, 'Data sources for drug utilization research in Latin American countries-A cross-national study: DASDUR-LATAM study', Pharmacoepidemiology and Drug Safety, vol. 31, no. 3, pp. 343-352. https://doi.org/10.1002/pds.5404

TY - JOUR

T1 - Data sources for drug utilization research in Latin American countries-A cross-national study

T2 - DASDUR-LATAM study

AU - Lopes, Luciane C

AU - Salas, Maribel

AU - Osorio-de-Castro, Claudia Garcia Serpa

AU - Leal, Lisiane Freitas

AU - Doubova, Svetlana V

AU - Cañás, Martín

AU - Dreser, Anahi

AU - Acosta, Angela

AU - Baldoni, Andre Oliveira

AU - de Cássia Bergamaschi, Cristiane

AU - Mota, Daniel Marques

AU - Gómez-Galicia, Diana L

AU - Sepúlveda-Viveros, Dino

AU - Delgado, Edgard Narvaez

AU - da Costa Lima, Elisangela

AU - Chandia, Felipe Vera

AU - Ferre, Felipe

AU - Marin, Gustavo H

AU - Olmos, Ismael

AU - Zimmermann, Ivan R

AU - Fulone, Izabela

AU - Roldán-Saelzer, Juan

AU - Sánchez-Salgado, Juan Carlos

AU - Castro-Pastrana, Lucila I

AU - de Souza, Luiz Jupiter Carneiro

AU - Beltrán, Manuel Machado

AU - Silva, Marcus Tolentino

AU - Mena, María Belén

AU - de França Fonteles, Marta Maria

AU - Urtasun, Martín A

AU - Tarapués, Mónica

AU - Hernández, Patricia Granja

AU - Medero, Natalia

AU - Herrera-Comoglio, Raquel

AU - Barberato-Filho, Silvio

AU - Galvão, Taís Freire

AU - Luiza, Vera Lucia

AU - Santa-Ana-Tellez, Yared

AU - Rodríguez-Tanta, Yesenia

AU - Elseviers, Monique

PY - 2022/3

Y1 - 2022/3

N2 - PURPOSE: Drug utilization research (DUR) contributes to inform policymaking and to strengthen health systems. The availability of data sources is the first step for conducting DUR. However, documents that systematize these data sources in Latin American (LatAm) countries are not known. We compiled the potential data sources for DUR in the LatAm region.METHODS: A network of DUR experts from nine LatAm countries was assembled and experts conducted: (i) a website search of the government, academic, and private health institutions; (ii) screening of eligible data sources, and (iii) liaising with national experts in pharmacoepidemiology (via an online survey). The data sources were characterized by accessibility, geographic granularity, setting, sector of the data, sources and type of the data. Descriptive analyses were performed.RESULTS: We identified 125 data sources for DUR in nine LatAm countries. Thirty-eight (30%) of them were publicly and conveniently available; 89 (71%) were accessible with limitations, and 18 (14%) were not accessible or lacked clear rules for data access. From the 125 data sources, 76 (61%) were from the public sector only; 46 (37%) were from pharmacy records; 43 (34%) came from ambulatory settings and; 85 (68%) gave access to individual patient-level data.CONCLUSIONS: Although multiple sources for DUR are available in LatAm countries, the accessibility is a major challenge. The procedures for accessing DUR data should be transparent, feasible, affordable, and protocol-driven. This inventory could permit a comparison of drug utilization between countries identifying potential medication-related problems that need further exploration.

AB - PURPOSE: Drug utilization research (DUR) contributes to inform policymaking and to strengthen health systems. The availability of data sources is the first step for conducting DUR. However, documents that systematize these data sources in Latin American (LatAm) countries are not known. We compiled the potential data sources for DUR in the LatAm region.METHODS: A network of DUR experts from nine LatAm countries was assembled and experts conducted: (i) a website search of the government, academic, and private health institutions; (ii) screening of eligible data sources, and (iii) liaising with national experts in pharmacoepidemiology (via an online survey). The data sources were characterized by accessibility, geographic granularity, setting, sector of the data, sources and type of the data. Descriptive analyses were performed.RESULTS: We identified 125 data sources for DUR in nine LatAm countries. Thirty-eight (30%) of them were publicly and conveniently available; 89 (71%) were accessible with limitations, and 18 (14%) were not accessible or lacked clear rules for data access. From the 125 data sources, 76 (61%) were from the public sector only; 46 (37%) were from pharmacy records; 43 (34%) came from ambulatory settings and; 85 (68%) gave access to individual patient-level data.CONCLUSIONS: Although multiple sources for DUR are available in LatAm countries, the accessibility is a major challenge. The procedures for accessing DUR data should be transparent, feasible, affordable, and protocol-driven. This inventory could permit a comparison of drug utilization between countries identifying potential medication-related problems that need further exploration.

U2 - 10.1002/pds.5404

DO - 10.1002/pds.5404

M3 - Article

C2 - 34957616

SN - 1053-8569

VL - 31

SP - 343

EP - 352

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

IS - 3

ER -

Data sources for drug utilization research in Latin American countries-A cross-national study: DASDUR-LATAM study

Abstract

Bibliographical note

Access to Document

Fingerprint

Cite this